These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1374262)

  • 21. Detection of competing DNA structures by thermal gradient gel electrophoresis: from self-association to triple helix formation by (G,A)-containing oligonucleotides.
    Arimondo PB; Garestier T; Hélène C; Sun JS
    Nucleic Acids Res; 2001 Feb; 29(4):E15. PubMed ID: 11160935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of RNAs that bind to duplex DNA at neutral pH.
    Soukup GA; Ellington AD; Maher LJ
    J Mol Biol; 1996 Jun; 259(2):216-28. PubMed ID: 8656424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical modification of oligonucleotides for therapeutic, bioanalytical and other applications.
    Bell NM; Micklefield J
    Chembiochem; 2009 Nov; 10(17):2691-703. PubMed ID: 19739190
    [No Abstract]   [Full Text] [Related]  

  • 24. Triple helix formation and the antigene strategy for sequence-specific control of gene expression.
    Praseuth D; Guieysse AL; Hélène C
    Biochim Biophys Acta; 1999 Dec; 1489(1):181-206. PubMed ID: 10807007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aptamers: selected oligonucleotides for therapy.
    Toulmé JJ
    Curr Opin Mol Ther; 2000 Jun; 2(3):318-24. PubMed ID: 11249626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence composition effects on the stabilities of triple helix formation by oligonucleotides containing N7-deoxyguanosine.
    Brunar H; Dervan PB
    Nucleic Acids Res; 1996 Jun; 24(11):1987-91. PubMed ID: 8668526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide analogues: an overview.
    Matteucci M
    Ciba Found Symp; 1997; 209():5-14; discussion 14-8. PubMed ID: 9383565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interference with MCP-1 gene expression by vector generated triple helix-forming RNA oligonucleotides.
    Kautz K; Schwarz M; Radeke HH
    Cell Mol Life Sci; 2005 Feb; 62(3):362-76. PubMed ID: 15723171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Team demonstrates the rational design of drugs from RNA sequence.
    Coaker H
    Future Med Chem; 2014 Apr; 6(5):495. PubMed ID: 24795921
    [No Abstract]   [Full Text] [Related]  

  • 30. Oligonucleotide therapeutics.
    Cohen JS
    Trends Biotechnol; 1992 Mar; 10(3):87-91. PubMed ID: 1371926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Medicinal Chemistry of Therapeutic Oligonucleotides.
    Wan WB; Seth PP
    J Med Chem; 2016 Nov; 59(21):9645-9667. PubMed ID: 27434100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HIV-1 activity by a triple-helix forming oligonucleotides targeted to polypurine tract on viral RNA.
    Hiratou T; Tsukahara S; Miyano-Kurosaki N; Takai K; Saito T; Yamamoto N; Takaku H
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(10-12):1721-34. PubMed ID: 11200268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted gene knockout mediated by triple helix forming oligonucleotides.
    Majumdar A; Khorlin A; Dyatkina N; Lin FL; Powell J; Liu J; Fei Z; Khripine Y; Watanabe KA; George J; Glazer PM; Seidman MM
    Nat Genet; 1998 Oct; 20(2):212-4. PubMed ID: 9771719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A SELEX primer.
    Fitzwater T; Polisky B
    Methods Enzymol; 1996; 267():275-301. PubMed ID: 8743323
    [No Abstract]   [Full Text] [Related]  

  • 35. Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation.
    Scomparin A; Polyak D; Krivitsky A; Satchi-Fainaro R
    Biotechnol Adv; 2015 Nov; 33(6 Pt 3):1294-309. PubMed ID: 25916823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic oligonucleotides: a review].
    Wang X; Xian J; Chen G; Peng H
    Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
    Jepsen JS; Sørensen MD; Wengel J
    Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA-based therapeutics and DNA delivery systems: a comprehensive review.
    Patil SD; Rhodes DG; Burgess DJ
    AAPS J; 2005 Apr; 7(1):E61-77. PubMed ID: 16146351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.